pomalidomide has been researched along with Cancer, Second Primary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM | 1 |
| Lentzsch, S; Pan, B | 1 |
1 review(s) available for pomalidomide and Cancer, Second Primary
| Article | Year |
|---|---|
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
1 other study(ies) available for pomalidomide and Cancer, Second Primary
| Article | Year |
|---|---|
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency | 2016 |